AI Drug Design
-
Absci Announces Pricing of Public Offering
Absci (ABSI) announced the pricing of its public offering of 16,670,000 shares at $3.00 per share, expecting gross proceeds of $50 million. Underwriters have a 30-day option to purchase an additional 2,500,500 shares. Absci will use the funds for program advancements, platform investment, and general corporate purposes. Morgan Stanley, J.P. Morgan, Jefferies, and TD Cowen are managing the offering, expected to close around July 25, 2025.
